Latest Patents News

Recce Pharmaceuticals has gained key regulatory and ethics approvals for its Phase 3 clinical trial in Indonesia and completed patient dosing for its Phase II trial, while securing a substantial A$6.75 million R&D tax rebate to bolster its financial position.

Purifloh Limited has made significant progress in its PFAS destruction technology, securing a $100,000 BRII feasibility grant while navigating challenges to resume trading on the ASX.

High-Tech Metals Limited intensifies its exploration efforts at the Werner Lake Project in Canada while appointing Warren Thorne as CEO to spearhead growth and asset acquisition strategies.

Saferoads Holdings reported a slight revenue dip in Q2 2024 but advanced toward selling its Road Safety Rentals business, while securing approval for a new crash barrier system.

Eagle Mountain Mining has strengthened its Silver Mountain copper project prospects, initiated tailings repurposing at Wedgetail, and launched a capital raise to reduce debt, while relinquishing Oracle Ridge mineral rights due to unaligned landowner terms.

NOVONIX has advanced its position in the battery materials sector with a conditional US$754 million loan commitment from the U.S. Department of Energy and binding offtake agreements with automotive giants Stellantis and PowerCo. These milestones underpin its expansion plans for synthetic graphite production in North America.

Wide Open Agriculture reports a 50% reduction in overheads alongside the development of a novel lupin-based tofu product, positioning itself for growth in the global plant protein market.

Papyrus Australia has taken significant strides in Q4 2024, signing a joint venture terms sheet in Vietnam, appointing new board members, and securing R&D tax incentives, positioning itself for expanded commercialization.

Vectus Biosystems reports completion of Phase Ib trials for its lead drug VB0004 and a robust cash position bolstered by a significant R&D tax refund, setting the stage for licensing discussions.

Aeris Environmental Ltd reported a 5% revenue increase to $766,000 in the December 2024 quarter, driven by strong margins and momentum in its AerisTech joint venture. The company’s expanding customer base and strategic partnerships signal promising growth in smart building solutions and consumables.

BCAL Diagnostics is poised to launch its innovative BREASTEST® breast cancer diagnostic test in early 2025, backed by recent NATA accreditation, patent acceptance, and a $2.6 million R&D tax offset.

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.